Executive Summary
The 29 filings for the S&P 500 Healthcare stream reveal a sector bifurcated between capital-intensive growth plays and financially distressed micro-caps. The most significant capital market event is the $628M IPO of Parabilis Medicines, which is burning cash rapidly (net loss of $145.9M in 2025, up 24% YoY) but has secured a $75M strategic investment from Regeneron.
The healthcare technology sub-sector shows severe financial strain, with AITX reporting a going concern qualification despite 26% YoY revenue growth, and Eco Science Solutions posting a massive $10.2M debt settlement gain that masks a $1.1M working capital deficit. The sector's capital allocation is mixed: while Esquire Financial is progressing on its accretive merger with Signature Bancorporation (all regulatory approvals received), Enveric Biosciences is resorting to dilutive ATM offerings ($2.4M additional shares) and Humacyte is authorizing a massive 570M share increase. Insider activity is notably absent across all filings, with no CEO/CFO transactions reported, suggesting management teams are not signaling conviction through personal investment. The dominant theme is a 'cash is king' environment where companies with strong balance sheets (Parabilis' pro-forma $957M cash) are positioned to survive, while those with negative working capital face existential risks.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 8-K · 10-K · S-1 · DEFA14A · DEF 14A · 10-Q · 13F · 425
Tracking the trend? Catch up on the prior S&P 500 Healthcare Sector SEC Filings digest from June 02, 2026.
Investment Signals (10)
- Parabilis Medicines ↓ (BULLISH)▲
IPO of 33.3M shares at $18.00 with $75M concurrent Regeneron private placement at 90% of IPO price, signaling strategic validation from a major pharma player. Pro-forma cash of $957M provides 6+ years of runway at current burn rate. Net loss increased 24% YoY to $145.9M in 2025, but Regeneron's willingness to invest at a discount suggests proprietary technology value
- Esquire Financial Holdings ↓ (BULLISH)▲
Received all regulatory approvals for Signature Bancorporation merger, with joint proxy mailed May 11. This is a clear catalyst for EPS accretion and market share expansion in the specialty banking space. No financial terms disclosed, but regulatory green light removes a key overhang
- AITX (MIXED)▲
Revenue grew 26% YoY to $7.7M with gross margin expanding 1,000 bps to 71%, while operating expenses remained flat. This demonstrates operating leverage and pricing power. However, the going concern qualification and $144K cash balance create extreme binary risk
- Eco Science Solutions ↓ (MIXED)▲
Total liabilities decreased 92.8% YoY from $16.7M to $1.2M, driven by a $10.2M debt settlement gain. Working capital deficit improved 93.3% to $1.1M. This is a balance sheet restructuring success, but operating cash flow deteriorated to -$368K from -$320K
- Cibus ↓ (NEUTRAL)▲
Appointed Craig Wichner as CEO, who joined the board only 7 months prior. Raised $62M in new investment during interim CEO's tenure. This leadership change signals a pivot to commercialization and capital strategy execution, but the rapid CEO transition (15 months interim) raises governance questions
- Ameriprise Financial ↓ (BULLISH)▲
Issued $750M in senior notes ($300M 4.8% due 2031, $450M 5.35% due 2036) at favorable rates. This debt issuance in a declining rate environment locks in low-cost capital for strategic initiatives or acquisitions
- Capital One Financial ↓ (NEUTRAL)▲
Filed to register 39,843 additional shares for resale from the Brex Inc. acquisition (closed April 7). The small size relative to 10.4M total registered shares suggests the Brex deal integration is progressing without major dilution surprises
- Virtu Financial ↓ (BULLISH)▲
CFO Cindy Lee received a new employment agreement with $500K base salary and 20,000 RSUs vesting over 3 years, with enhanced change-in-control severance (2.5x salary + bonus). This retention package signals board confidence in leadership continuity through June 2029
- Stifel Financial ↓ (NEUTRAL)▲
Increased authorized common shares by 45.5% from 200M to 291M and preferred from 1M to 3M. This provides flexibility for future acquisitions or capital raises, but could also signal impending dilution. The 91M share increase is substantial for a firm with ~100M shares outstanding
- Synchrony Financial ↓ (NEUTRAL)▲
Filed monthly charge-off and delinquency statistics for 13 months through May 2026. While no specific figures were disclosed in the filing text, the continued monthly disclosure suggests consumer credit trends remain a key focus for investors
Risk Flags (9)
- AITX - Going Concern [HIGH RISK]▼
Auditors issued a going concern qualification with only $144K cash on hand, $165M accumulated deficit, and negative equity of $49M (liabilities $58M vs assets $9M). Despite 26% revenue growth, the company cannot fund operations without external financing. Shares outstanding collapsed from 14.4B to 267.9M, indicating a reverse split
- Parabilis Medicines - Cash Burn↓ [MODERATE RISK]▼
Net losses increased 24% YoY from $117.9M to $145.9M in 2025, with Q1 2026 loss of $45.3M (up 18% from $38.3M). At this burn rate, the $957M pro-forma cash provides only ~5-6 years of runway, but clinical-stage biotechs often accelerate spending as trials advance
-
Cash used in operations increased 15% to $367,781 from $319,829, despite the massive debt settlement gain. The accumulated deficit stands at $69.3M, and the going concern warning persists. The debt settlement is a one-time event that doesn't fix the underlying business model
- Enveric Biosciences - Dilutive Financing↓ [HIGH RISK]▼
Filed to sell an additional $2.4M of common stock via ATM, after already selling $4.5M under the same agreement. Combined with the earlier investor presentation filing, this signals urgent capital needs. The company is a development-stage biotech with no approved products, making equity dilution a recurring risk
- Humacyte - Massive Authorized Share Increase↓ [MODERATE RISK]▼
Increased authorized capital stock to 570M shares (550M common, 20M preferred) from an undisclosed prior amount. This is a massive potential dilution event, especially for a pre-revenue biotech. The filing provides no explanation for the increase
- B. Riley Financial - Debt-for-Equity Dilution↓ [MODERATE RISK]▼
Issued 2.06M shares to DBA Trading in exchange for cancellation of $780K in senior notes across 4 series. While this reduces debt, it dilutes existing shareholders by ~5.4% (total shares now 40.2M). No cash was received, and the exchanges were done at distressed levels
- Conexeu Sciences - Penny Warrant Exercises↓ [MODERATE RISK]▼
Issued 416,667 shares at $0.40 for $166,667 and 100,000 shares at $0.001 for $100. The $0.001 exercise price is essentially a giveaway, and the 416,667 incentive warrants at $2.30 create further dilution risk. Total shares outstanding reached 26.8M
- Zeo ScientifiX - No Financial Substance↓ [LOW RISK]▼
Expanded Medical Advisory Board with 9 new members, but the filing contains zero financial data. For a company in regenerative medicine, this is a 'science fair' announcement that provides no insight into revenue, pipeline, or cash position
- ▼
Audit fees decreased slightly from $539K to $533K, but audit-related fees jumped from $0 to $71K. The increase in non-audit fees could raise independence concerns, though the amounts are small relative to the fund's size
Opportunities (9)
- Parabilis Medicines / IPO Catalyst↓ (OPPORTUNITY)◆
The $628M IPO with Regeneron's $75M strategic investment at a 10% discount to IPO price creates a unique opportunity. Regeneron's due diligence and willingness to invest at a premium to the IPO price (90% of $18 = $16.20) suggests the underlying technology is undervalued. The $957M pro-forma cash provides a multi-year runway for clinical development
- Esquire Financial / Merger Arbitrage↓ (OPPORTUNITY)◆
The Signature Bancorporation merger has received all regulatory approvals, with the joint proxy mailed May 11. The deal is now in the final stages, creating a classic merger arbitrage opportunity. Esquire's stock (ESQ) should re-rate as the closing date approaches, with minimal regulatory risk remaining
- AITX / Turnaround Potential (SPECULATIVE OPPORTUNITY)◆
Despite the going concern, AITX's core metrics are improving: 26% revenue growth, 1,000 bps gross margin expansion to 71%, and flat operating expenses. If the company can secure financing (even at dilutive terms), the operating leverage could drive significant value. The 100+ dealer network and Fortune 500 end users provide a credible revenue base
- Eco Science Solutions / Balance Sheet Restructuring↓ (SPECULATIVE OPPORTUNITY)◆
The 92.8% reduction in total liabilities and 93.3% improvement in working capital deficit represent a dramatic balance sheet cleanup. If the company can now focus on operations without the debt overhang, the improved financial position could attract new investors or strategic partners
- Ameriprise Financial / Debt Issuance Lock-In↓ (OPPORTUNITY)◆
The $750M debt issuance at 4.8% and 5.35% rates is attractive in the current rate environment. Ameriprise can use this low-cost capital for strategic acquisitions, share buybacks, or organic growth. The 5-year and 10-year maturities provide long-term funding stability
- Virtu Financial / CFO Retention Signal↓ (OPPORTUNITY)◆
The enhanced employment agreement for CFO Cindy Lee, including 20,000 RSUs and change-in-control severance, signals board confidence in the company's strategic direction. The 3-year vesting and June 2029 term suggest management expects stability and growth
- Cibus / New CEO Catalyst↓ (OPPORTUNITY)◆
Craig Wichner's appointment as CEO, combined with the $62M raised during the interim period, could signal a new phase of commercialization. The succession plan suggests the board is preparing for accelerated growth, and the clean break (both Wichner and Beetham resigned from the board) indicates a focused management structure
- Capital One Financial / Brex Integration↓ (OPPORTUNITY)◆
The additional 39,843 shares registered for resale from the Brex acquisition represent only 0.4% of the 10.4M total registered shares. This small incremental dilution suggests the integration is proceeding smoothly, and the Brex technology could provide a competitive advantage in the fintech space
- Federal Home Loan Bank of New York / Debt Issuance↓ (OPPORTUNITY)◆
The $5.6B in consolidated obligations across 10 tranches with maturities through 2028 provides a liquid, high-quality fixed-income opportunity. The mix of variable-rate floaters and callable fixed-rate bonds offers yield enhancement for income-focused investors
Sector Themes (6)
- Cash is King: Balance Sheet Strength Dictates Survival◆
The filings reveal a stark divide between well-capitalized companies (Parabilis with $957M pro-forma cash) and cash-strapped micro-caps (AITX with $144K, Eco Science with negative working capital). Companies with strong balance sheets are positioned to weather clinical development timelines, while those with going concern qualifications face existential risk regardless of revenue growth.
- Dilution as a Financing Tool of Last Resort◆
Multiple companies are resorting to equity dilution to stay afloat: Enveric ($6.9M total ATM sales), Conexeu (516,667 shares issued for minimal proceeds), B. Riley (2.06M shares for debt cancellation), and Humacyte (570M authorized shares). This pattern suggests traditional debt financing is unavailable for these companies, signaling broader credit market tightness for small-cap healthcare.
- M&A Activity Signals Sector Consolidation◆
Two significant M&A events are progressing: Capital One's Brex acquisition (closing April 7) and Esquire Financial's Signature Bancorporation merger (regulatory approvals received). Both are in the financial services/healthcare intersection, suggesting consolidation is occurring in the specialized lending and payments space.
- Leadership Churn Reflects Strategic Pivots◆
Cibus' CEO change (15-month interim tenure) and the Federal Home Loan Bank of New York's CFO appointment (Brinda Bhattacharjee) indicate that companies are refreshing management teams to execute new strategies. The Cibus transition from a scientist-led (Beetham) to a commercial-focused (Wichner) CEO signals a pivot from R&D to revenue generation.
- Debt Restructuring Masks Operating Weakness◆
Eco Science Solutions' $10.2M debt settlement gain and B. Riley's debt-for-equity exchanges highlight a trend where companies are using financial engineering to improve balance sheets while underlying operations remain challenged. Investors should focus on operating cash flow trends rather than headline net income figures.
- Regulatory Approvals as Key Catalysts◆
The Esquire Financial/Signature Bancorporation merger receiving all regulatory approvals demonstrates that the regulatory environment for healthcare/financial services M&A remains constructive. This could signal a wave of similar transactions as companies seek scale and efficiency.
Watch List (8)
-
The IPO is expected to price at $18.00 with the Regeneron private placement at $16.20. Watch for the actual pricing and first-day trading performance, which will signal institutional demand for clinical-stage biotech. The overallotment option (5M shares) could add $83.8M to proceeds [Date: IPO expected within weeks of June 9 filing]
-
With all regulatory approvals received, the Signature Bancorporation merger is in its final stages. Watch for shareholder vote results and the actual closing date. The joint proxy was mailed May 11, suggesting a vote in late June or early July [Date: Shareholder vote expected Q3 2026]
- AITX / Financing Event👁
With only $144K cash on hand and a going concern qualification, AITX must raise capital imminently. Watch for any 8-K filings related to debt or equity financing, which could be highly dilutive given the recent reverse split. The company's ability to secure financing will determine survival [Date: Imminent - within weeks]
-
The company has now sold $6.9M under its ATM agreement and filed for an additional $2.4M. Watch for continued dilution and any updates on clinical trial progress that could justify the capital raise [Date: Ongoing - monitor monthly]
-
The 570M authorized share increase is massive for a pre-revenue biotech. Watch for any subsequent filings indicating actual share issuance, which would signal the purpose of the authorization (acquisition, financing, or employee compensation) [Date: No specific date - monitor for S-1 or 8-K filings]
-
New CEO Craig Wichner's focus on commercialization and capital strategy execution should yield tangible milestones. Watch for partnership announcements, product launches, or revenue guidance in upcoming quarters [Date: Q3 2026 earnings call expected August]
-
The monthly charge-off and delinquency statistics for the 13 months ended May 2026 will provide early warning signals for consumer credit health. Given the economic uncertainty, any deterioration in these metrics could signal broader consumer stress [Date: Monthly filings expected around 9th of each month]
-
New CFO Brinda Bhattacharjee starts June 3 with a $600K salary and $417K sign-on. Watch for any strategic changes in the bank's funding strategy or risk management approach under new financial leadership [Date: Transition period through June 30]
Filing Analyses
(29)
09-06-2026
AITX filed its audited FY2026 10-K, confirming revenue grew 26% YoY to $7.7M and gross margin expanded to 71% from 61%, while operating expenses remained flat. However, the company reported a loss from operations of $11.9M, an accumulated deficit of ~$165M, and only $144K cash on hand, with auditors issuing a going concern qualification. The company also detailed its three-pillar operating strategy (Stationary, Mobile, Agentic AI) and noted that its residential product line (RAD-R) generated immaterial revenue, substantially below expectations.
- · Auditors issued a going concern qualification due to recurring net losses, negative working capital, ~$165M accumulated deficit, and dependence on external financing.
- · Total liabilities of ~$58M exceed total assets of ~$9M, resulting in a stockholders' deficit of ~$49M.
- · Cash on hand was only ~$144K, insufficient to fund operations for any extended period without additional financing.
- · Approximately 96% of outstanding loans payable are owed to entities controlled by a single individual, creating concentration risk.
- · The residential product line (RAD-R) generated immaterial revenue in FY2026, substantially below expectations.
- · ROAMEO commenced commercial billing in May 2026 after ~$20M in cumulative development investment.
- · The company has experienced significant common share dilution, including issuances under an equity financing arrangement of up to $30M.
- · The company has not been profitable in any fiscal year of its operating history.
- · RAD-G (agentic AI platform) has not yet produced revenue commensurate with management's expectations.
- · The company serves customers including one Fortune Top 10 enterprise and several additional Fortune 500 enterprises.
09-06-2026
AITX filed its 10-K for the fiscal year ended February 28, 2026, reporting a 26% increase in revenue to $7.7M, driven by a 37% surge in device rental activities to $6.9M. However, direct sales of goods and services declined 24% to $825K, and the company continued to operate at a net loss of $14.5M, though this was a 23% improvement from the prior year's $18.9M loss. The company also engaged in extensive debt-for-equity exchanges and share issuances, with outstanding shares rising from 9.2B to 14.4B over the two-year period, and then dropping sharply to 267.9M by February 28, 2026, reflecting a reverse stock split or similar restructuring.
- · The company's authorized dealer network has grown to over 100 dealers across the United States, Canada, and the European Union.
- · Enterprise and Fortune 500 end users serve as both a revenue base and credibility base for SARA adoption.
- · Shares outstanding dropped dramatically from 14,412,453,768 on Feb 28, 2025 to 267,872,804 on Feb 28, 2026, indicating a likely reverse stock split.
- · During the period March 1, 2025 to February 28, 2026, the company issued 50,403,802 shares through other registered sales.
- · The company recorded a loss on disposal of fixed assets of $22,312 in FY 2026, compared to $0 in the prior year.
- · Operating lease cost and rent increased 5% YoY to $251,883.
09-06-2026
Cipher Digital Inc. (CIFR) announced that its wholly-owned subsidiary Stingray Compute LLC priced an $810.0M aggregate principal amount of 6.000% senior secured notes due 2031 at 99.750% of par. The offering is expected to close on June 15, 2026, and is being sold to qualified institutional buyers and non-U.S. persons under Rule 144A and Regulation S. There is no prior-period comparative financial data in this filing to calculate period-over-period changes.
- · Notes are being sold exclusively to qualified institutional buyers under Rule 144A and to non-U.S. persons under Regulation S.
- · The offering is expected to close on June 15, 2026, subject to customary closing conditions.
- · The filing includes cautionary forward-looking statements and incorporates risk factors from the 2025 10-K and Q1 2026 10-Q.
09-06-2026
News Corp filed an 8-K on June 9, 2026, disclosing that it has provided daily transaction disclosures to the Australian Securities Exchange (ASX) under its existing $1 billion stock repurchase program. The filing includes forward-looking statements regarding the company's intent to repurchase shares from time to time, subject to market conditions and other factors.
- · The repurchase program authorizes up to $1 billion in aggregate of Class A and Class B common stock.
- · Disclosures were provided to the ASX on the dates noted in Exhibits 99.1 through 99.4.
- · The company disclaims any obligation to update forward-looking statements except as required by law.
09-06-2026
Enveric Biosciences, Inc. filed an 8-K on June 8, 2026, announcing the release of its Q2 2026 Investor Presentation, which management intends to use in discussions with investors, analysts, and other stakeholders. The presentation is furnished under Regulation FD and is available on the company's website. No specific financial figures or performance data were disclosed in the filing itself.
- · The Investor Presentation is furnished as Exhibit 99.1 and incorporated by reference into the 8-K.
- · The presentation is available on the company's website at https://www.enveric.com/investors/events/.
- · The information in this 8-K is not deemed 'filed' for purposes of Section 18 of the Exchange Act and is not incorporated by reference into any SEC filings unless expressly set forth.
09-06-2026
Axos Financial, Inc. announced that its subsidiary Axos Bank received OCC approval for a previously disclosed deposit acquisition, which is expected to close later in 2026.
- · The approval was granted on June 8, 2026.
- · The transaction was initially disclosed on April 23, 2026.
09-06-2026
Synchrony Financial filed an 8-K on June 9, 2026, furnishing monthly charge-off and delinquency statistics for the thirteen months ended May 31, 2026, under Regulation FD. The company intends to continue providing these statistics monthly, with quarter-end data released alongside quarterly financial results. No specific financial figures or performance trends were disclosed in the filing text itself.
- · The filing is a Regulation FD disclosure, not a filed report, and is not incorporated by reference into other SEC filings.
- · Exhibit 99.1 contains the actual monthly charge-off and delinquency statistics for the thirteen months ended May 31, 2026.
- · The company will continue to furnish these statistics monthly, with quarter-end data released alongside quarterly financial results.
09-06-2026
Parabilis Medicines, Inc. filed an S-1/A registration statement for an initial public offering of 33,333,334 shares of common stock at an assumed price of $18.00 per share, with an overallotment option for up to 5,000,000 additional shares. The company expects net proceeds of approximately $553.1 million from the offering (or $636.8 million if the overallotment is exercised in full), plus an additional $75.0 million from a concurrent private placement with Regeneron. However, the company is not yet profitable, with net losses increasing from $117.9 million in 2024 to $145.9 million in 2025, and a net loss of $45.3 million for the three months ended March 31, 2026, compared to $38.3 million in the same period of 2025.
- · The company has granted the underwriters a 30-day overallotment option to purchase up to 5,000,000 additional shares.
- · Regeneron has agreed to purchase approximately $75.0 million in shares at 90% of the IPO price in a concurrent private placement, contingent on the IPO closing.
- · Pro forma as adjusted cash and cash equivalents after the offering and private placement would be approximately $957.1 million.
- · The company had an accumulated deficit of $586.8 million as of March 31, 2026.
- · Pro forma net loss per share (basic and diluted) for the year ended December 31, 2025 was $(1.81), and for the three months ended March 31, 2026 was $(0.56).
- · The company's convertible preferred stock balance of $814.5 million will convert to common and non-voting common stock upon the closing of the offering.
- · Interest income decreased 47.2% from $6.4 million in 2024 to $3.4 million in 2025, but increased 93.2% from $1.3 million in Q1 2025 to $2.4 million in Q1 2026.
- · Sublease income from a related party was $4.2 million in both 2024 and 2025, but was $0 in Q1 2026 compared to $1.1 million in Q1 2025.
- · The company effected a 1-for-1.5389 reverse stock split on June 3, 2026.
- · The proposed Nasdaq Global Market trading symbol is 'PBLS'.
09-06-2026
Zeo ScientifiX, Inc. announced on June 9, 2026, the expansion of its Medical Advisory Board with the addition of nine physicians and scientific innovators in regenerative and longevity medicine. This filing contains no financial or operational performance data, and no comparisons to prior periods are available.
- · The event was reported under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits).
- · The press release is attached as Exhibit 99.1 to the 8-K filing.
- · The company is incorporated in Nevada and headquartered in Davie, Florida.
09-06-2026
Stifel Financial Corp. filed an 8-K on June 9, 2026, announcing an amendment to its Second Restated Certificate of Incorporation to increase authorized common shares from 200 million to 291 million and authorized preferred shares from 1 million to 3 million. The amendment was approved by the board and shareholders, and executed by Chairman and CEO Ronald J. Kruszewski.
- · The amendment increases authorized common stock from 200 million to 291 million shares and preferred stock from 1 million to 3 million shares.
- · The amendment was adopted under Section 242 of the Delaware General Corporation Law.
- · The filing includes items 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers), 5.03 (Amendments to Articles of Incorporation or Bylaws), 5.07 (Submission of Matters to a Vote of Security Holders), and 9.01 (Financial Statements and Exhibits).
09-06-2026
Conexeu Sciences Inc. issued 416,667 shares upon exercise of common stock purchase warrants for gross proceeds of approximately $166,667 on June 4, 2026, and issued 100,000 shares upon exercise of performance warrants for gross proceeds of $100 on June 8, 2026. The company also granted 416,667 incentive warrants with a $2.30 exercise price as part of a warrant exercise incentive program. Following these exercises, total shares outstanding increased to 26,758,330.
- · The incentive warrants have a 36-month term and an exercise price of $2.30 per share.
- · The warrant exercise incentive program was adopted effective October 31, 2025, and expires June 30, 2026.
- · The performance warrants were exercised at $0.001 per share, yielding only $100 in proceeds.
- · The company's common stock trades on Nasdaq under the symbol CNXU.
- · The company is an emerging growth company.
09-06-2026
Humacyte, Inc. filed a Certificate of Amendment to its Second Amended and Restated Certificate of Incorporation on June 9, 2026, increasing its authorized capital stock from an undisclosed prior amount to 570,000,000 shares (550,000,000 common and 20,000,000 preferred), each with a par value of $0.0001 per share. The amendment was approved by the board of directors and stockholders, and became effective upon filing with the Delaware Secretary of State. No financial results or operational metrics were disclosed in this filing.
- · The original certificate of incorporation was filed on July 1, 2020, with subsequent amendments on September 17, 2020, August 26, 2021, and June 10, 2025.
- · The amendment was adopted by the board of directors and stockholders in accordance with Sections 228 and 242 of the DGCL.
- · The par value per share remains $0.0001 for all classes of capital stock.
09-06-2026
FS Specialty Lending Fund filed definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting of shareholders, to be held on August 3, 2026. The sole voting items are the election of Charles P. Pizzi and Pedro A. Ramos as Class I trustees, each serving until the 2029 annual meeting, with the Board recommending a vote "For" each nominee.
- · Voting deadline is August 2, 2026 at 11:59 PM ET, with the in-person meeting on August 3, 2026 at 1:00 PM ET at 3025 JFK Blvd., OFC 500, Philadelphia, PA 19104.
- · Shareholders may request paper or email copies of proxy materials before July 20, 2026.
- · The notice is not a votable ballot; shareholders must vote via www.ProxyVote.com or in person.
09-06-2026
FS Specialty Lending Fund filed its definitive proxy statement (DEF 14A) for the 2026 annual meeting, recommending the election of trustee nominees Charles P. Pizzi and Pedro A. Ramos. The fund is externally managed with no employees; executive officers receive no direct compensation from the fund. Audit fees decreased slightly from $539,000 in FY2024 to $533,489 in FY2025, while audit-related fees rose from $0 to $71,000. All Section 16(a) filing requirements were timely satisfied during fiscal 2025.
- · The fund is externally managed under an Investment Advisory Agreement effective October 28, 2025 and an Administration Agreement dated October 28, 2025.
- · Trustees who are also executive officers receive no compensation from the fund; only independent trustees receive retainers and meeting fees.
- · All Section 16(a) filing requirements were timely satisfied during fiscal year ended December 31, 2025.
- · Ernst & Young has served as independent auditor since fiscal year 2013 through 2025.
- · Tax fees and all other fees billed by Ernst & Young were $0 for both FY2025 and FY2024.
- · Shareholder proposals for the 2027 annual meeting must be received by May 5, 2027.
- · The board unanimously recommends voting FOR each trustee nominee.
09-06-2026
Enveric Biosciences filed a prospectus supplement on June 9, 2026, to offer an additional $2,425,000 of common stock under its existing ATM agreement with H.C. Wainwright & Co. Prior to this, the company had already sold $4,483,711.04 under the same agreement. The filing includes a legal opinion from Greenberg Traurig, LLP.
- · The ATM Agreement was dated April 9, 2025.
- · The legal opinion regarding the legality of the shares is filed as Exhibit 5.1.
09-06-2026
BRC Group Holdings, Inc. (formerly B. Riley Financial, Inc.) disclosed unregistered sales of equity securities in privately negotiated exchanges under Section 3(a)(9) of the Securities Act. On May 14 and June 4, 2026, the company issued a total of 2,060,683 shares of common stock to DBA Trading, LLC in exchange for the cancellation of 780,070 units of senior notes across four series (RILYN, RILYG, RILYT, RILYZ). The company received no cash proceeds from these transactions, and the exchanges resulted in a reduction of outstanding debt but dilution for existing shareholders.
- · The exchanges were conducted under Section 3(a)(9) exemption, meaning no commission or remuneration was paid for solicitation.
- · The company's total common shares outstanding increased to 40,194,696 as of June 4, 2026, reflecting dilution from the 2,060,683 newly issued shares.
- · The filing was triggered because the aggregate unregistered sales since the last report exceeded 5% of the outstanding common stock as of May 5, 2026.
09-06-2026
Parabilis Medicines, Inc. filed an S-1MEF registration statement on June 9, 2026, to register an additional 191,666 shares of common stock (including 25,000 shares subject to the underwriters' over-allotment option) for its existing public offering. This filing is a Rule 462(b) 'staple' registration that increases the offering size by no more than 20% of the maximum aggregate offering price previously set. The filing does not contain any financial results or operational updates.
- · The filing is made under Rule 462(b) and incorporates by reference the earlier S-1 registration statement (File No. 333-296032) declared effective on June 9, 2026.
- · The company is a non-accelerated filer, a smaller reporting company, and an emerging growth company.
- · Principal executive offices are located at 30 Acorn Park Drive, Cambridge, MA 02140.
09-06-2026
Columbia Financial, Inc. filed its quarterly report (10-Q) for the quarter ended March 31, 2026, including certifications by the CEO and CFO. The filing is a routine periodic disclosure with no specific financial figures provided in the excerpt.
09-06-2026
Cibus, Inc. announced the appointment of board member Craig Wichner as CEO, while Peter Beetham transitions from Interim CEO back to President and COO. The leadership change is part of a succession plan aimed at accelerating commercialization and capital strategy execution. The company highlighted raising over $62 million in new investment during Beetham's interim tenure, but no specific revenue or financial performance metrics were disclosed.
- · Craig Wichner joined the Cibus board in November 2025 and was appointed CEO in June 2026.
- · Peter Beetham served as Interim CEO for 15 months before returning to President and COO.
- · Both Wichner and Beetham resigned from the Board of Directors as part of the reorganization.
- · The Trait Machine process was cited by Fast Company Magazine as one of the most innovative products in 2024.
- · Cibus is not a seed company but a technology company that licenses traits to seed companies for royalties.
09-06-2026
Enterprise Financial Services Corp filed an 8-K on June 9, 2026, disclosing that it made an investor presentation available for meetings with investors, analysts, and other interested parties. The presentation is filed as Exhibit 99.1 and incorporated by reference. No financial results or material changes were reported in this filing.
- · The filing is an 8-K under Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits).
- · The investor presentation is intended for use in meetings with investors, analysts, and other interested parties.
- · The registrant is incorporated in Delaware with principal executive offices in St. Louis, Missouri.
- · Common stock (EFSC) and depositary shares for Series A preferred stock (EFSCP) are listed on the Nasdaq Global Select Market.
09-06-2026
The Federal Home Loan Bank of New York issued a series of consolidated obligations totaling approximately $5.6125 billion across ten tranches on trade dates June 3-5, 2026. The issuances include both non-callable variable-rate single index floaters and callable fixed/variable-rate bonds with maturities ranging from June 2027 to June 2028. The largest single tranche is a $1.75 billion non-callable variable floater maturing September 2027, while the smallest is a $15 million callable fixed-rate bond at 4.25% coupon.
- · Trade dates span June 3-5, 2026, with settlement dates from June 5 to June 11, 2026.
- · Maturities range from June 4, 2027 to September 8, 2028.
- · Next pay dates for all tranches are in September 2026 (September 4, 5, 8, 9, or 10).
- · Two tranches are callable: a $15M fixed-rate bond (4.25% coupon, next call date June 8, 2027) and a $60M variable floater (next call date June 8, 2027).
- · All non-callable tranches are variable-rate single index floaters.
- · The filing does not disclose the specific index or spread for the variable-rate bonds.
09-06-2026
Robinswood Financial LLC filed its Q1 2026 13F-HR, reporting a portfolio of 192 holdings with a total market value of approximately $79.3 million as of March 31, 2026. The portfolio is heavily weighted toward ETFs, with top positions including the Dimensional International Value ETF ($13.2M), Dimensional International Small Cap ETF ($9.4M), and iShares Core International Aggregate Bond ETF ($7.0M). No prior period data is provided in this filing, so period-over-period comparisons are not available.
- · The portfolio includes 192 holdings with a total value of $79,346,284.
- · The largest single stock position is Costco Wholesale Corp at $1,662,490 (1,668 shares).
- · Other notable stock positions include Exxon Mobil ($568,068, 3,348 shares), NVIDIA ($432,187, 2,478 shares), and Alphabet Class A ($289,897, 1,008 shares).
- · The portfolio has a significant ETF allocation, with the top 10 holdings by value being ETFs.
- · The filing indicates all holdings are held with sole voting and dispositive power.
- · No period-over-period comparisons are possible as this is a first-time filing or no prior data is included.
09-06-2026
Federal Home Loan Bank of New York appointed Brinda Bhattacharjee, 43, as Chief Financial Officer effective June 3, 2026. She will lead Financial Accounting, Management Reporting, and Strategic Planning and serve on the Management Committee. Her compensation includes a $600,000 annual base salary and a $417,525 sign-on payment, with prior CFO Kevin Neylan continuing as a consultant through June 30, 2026 for transition support.
- · Bhattacharjee previously served as Corporate Treasurer at StubHub and Global Treasurer/Interim CFO at MoneyGram.
- · She spent over seven years at Goldman Sachs, most recently as Managing Director and COO for Transaction Banking.
- · No family relationships or material interests requiring disclosure under Item 404(a) exist.
- · Kevin Neylan will remain as consultant through June 30, 2026.
09-06-2026
Ameriprise Financial issued $750M in senior notes on June 9, 2026, consisting of $300M of 4.800% notes due 2031 and $450M of 5.350% notes due 2036. The notes were sold via an underwriting agreement with BofA Securities, Citigroup Global Markets, and J.P. Morgan Securities. No period-over-period comparisons are available as this is a standalone debt issuance event.
- · The notes were issued under a prospectus supplement dated June 4, 2026, to a prospectus dated February 23, 2024, as part of a Form S-3 registration statement (No. 333-277307).
- · The underwriting agreement was entered into on June 4, 2026, with BofA Securities, Citigroup Global Markets, and J.P. Morgan Securities acting as representatives of the underwriters.
- · The 2031 Notes mature in 2031 (5-year term) and the 2036 Notes mature in 2036 (10-year term).
- · The opinion of Faegre Drinker Biddle & Reath LLP is included as an exhibit.
09-06-2026
ECO SCIENCE SOLUTIONS, INC. filed its FY2026 10-K annual report, reporting a net loss of $958,352 in operating expenses, a significant improvement from $1,025,139 in FY2025. The company recorded a substantial gain on debt settlement of $10,181,351 and a gain on debt forgiveness of $343,833, leading to total other income of $10,400,571 compared to an expense of $76,549 in the prior year. However, the company continues to face a working capital deficit of $1,124,029 and an accumulated deficit of $69,284,053, with cash used in operations increasing to $367,781 from $319,829, and the report includes a going concern warning.
- · The company recorded a gain on debt settlement of $10,181,351 and a gain on debt forgiveness of $343,833 in FY2026, compared to none in FY2025.
- · Total liabilities decreased by 92.8% from $16,669,544 to $1,194,853 year-over-year.
- · Working capital deficit improved from $16,662,272 to $1,124,029, a reduction of 93.3%.
- · Accumulated deficit decreased by 12.0% from $78,726,272 to $69,284,053.
- · Net cash used in operating activities increased by 15.0% to $367,781, indicating higher cash burn.
- · The company had no investing activities in either FY2026 or FY2025.
- · Cash increased significantly from $2,817 to $32,699, but remains minimal.
- · The report includes a going concern warning and references a May 4, 2026 reverse stock split.
- · Intangible assets remained unchanged at $100,000.
09-06-2026
Capital One Financial Corporation filed an 8-K on June 9, 2026, to register an additional 39,843 shares of common stock for resale by selling security holders, increasing the total registered shares to 10,385,749. These shares were issued as consideration in connection with the acquisition of Brex Inc., which closed on April 7, 2026. The filing does not include any financial results or period-over-period comparisons.
- · The Resale Prospectus Supplement No. 2 amends and supplements the Initial Resale Prospectus Supplement dated April 23, 2026.
- · The shares were issued as consideration in connection with the acquisition of Brex Inc., which closed on April 7, 2026.
- · The filing includes an opinion and consent from Wachtell, Lipton, Rosen & Katz as exhibits.
09-06-2026
Esquire Financial Holdings, Inc. (ESQ) announced on June 9, 2026, that it has received all regulatory approvals for its merger with Signature Bancorporation, Inc. The merger is proceeding toward closing, with a joint proxy statement/prospectus already mailed to shareholders on May 11, 2026. While the receipt of approvals is a positive milestone, the filing contains extensive forward-looking risk factors, including potential failure to close, integration challenges, and dilution from issuing additional shares.
- · The joint proxy statement/prospectus was mailed to stockholders of Esquire and shareholders of Signature on or about May 11, 2026.
- · Esquire's common stock is traded on Nasdaq under the symbol ESQ.
- · The merger agreement is subject to conditions including shareholder approvals and other customary closing conditions.
- · Esquire filed a registration statement on Form S-4 with the SEC in connection with the proposed transaction.
- · Risk factors include potential adverse effects on ESQ's stock price, integration difficulties, and dilution from issuing additional shares.
09-06-2026
Esquire Financial Holdings, Inc. (ESQ) announced on June 9, 2026, that it has received all regulatory approvals for its merger with Signature Bancorporation, Inc. The merger is proceeding toward closing, with a joint proxy statement/prospectus already mailed to shareholders on May 11, 2026. The filing does not disclose any financial terms or performance metrics, and forward-looking statements caution that actual results may differ materially due to integration risks, market conditions, and other factors.
- · The joint proxy statement/prospectus was mailed to stockholders on or about May 11, 2026.
- · The merger is subject to customary closing conditions, including shareholder approvals.
- · Esquire filed a registration statement on Form S-4 with the SEC in connection with the transaction.
- · The filing includes extensive forward-looking statements and risk factors related to the merger.
09-06-2026
Virtu Financial entered into an amended employment agreement with CFO Cindy Lee, increasing her base salary to $500,000 and granting a special long-term equity award of 20,000 restricted shares/RSUs vesting over three years. The agreement runs through June 2029 with enhanced severance benefits, including 2.5x salary plus bonus upon a change-in-control termination. No negative or flat metrics are present as this is a compensation update.
- · The agreement has an initial term expiring June 30, 2029, with automatic one-year renewals.
- · Severance upon qualifying termination (non-change-in-control) is greater of 1x base salary or base salary through end of term.
- · Change-in-control termination severance is 2.5x (base salary + most recent annual bonus).
- · Benefits continuation period is 12 months (or longer) for non-CIC, and 24 months (or longer) for CIC.
- · Ms. Lee remains subject to a restrictive covenant agreement with 12-month non-compete and non-solicit.
Get daily alerts with 10 investment signals, 9 risk alerts, 9 opportunities and full AI analysis of all 29 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: S&P 500 Healthcare Sector SEC Filings
🇺🇸 More from United States
View all →June 02, 2026
US Pre-Market SEC Filings Roundup — June 02, 2026
US Pre-Market SEC Filings Roundup
June 02, 2026
Global High-Priority Regulatory Events — June 02, 2026
Global High-Priority Regulatory Events
June 02, 2026
US Corporate Board Director Changes SEC Filings — June 02, 2026
US Corporate Board Director Changes SEC Filings
June 02, 2026
US Merger & Acquisition SEC Filings — June 02, 2026
US Merger & Acquisition SEC Filings